Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. He is co-founder of a number of biotech companies and is an active board member in several of Aglaia’s portfolio companies. Before founding Aglaia in 2003, he was Program Director of the NDDO Research Foundation. He held several positions with NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 until 1997 Mark was Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 until 1993.